D.E. Shaw & Co
RNAM

D.E. Shaw & Co’s Avidity Biosciences RNAM Stock Holding History

D.E. Shaw & Co’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,577
Closed -$504K – 4946
2025
Q3 		$504K Sell
11,577
-225,820
-95% -$9.13M ﹤0.01% 3860
2025
Q2 		$6.74M Buy
+237,397
New +$7.08M ﹤0.01% 1799
2025
Q1 		– Sell
-558,969
Closed -$16.3M – 4667
2024
Q4 		$16.3M Sell
558,969
-549,678
-50% -$23M 0.01% 1169
2024
Q3 		$50.9M Buy
1,108,647
+369,608
+50% +$16M 0.04% 499
2024
Q2 		$30.2M Buy
739,039
+707,773
+2,264% +$20.3M 0.03% 668
2024
Q1 		$798K Sell
31,266
-10,220
-25% -$160K ﹤0.01% 3237
2023
Q4 		$375K Sell
41,486
-111,793
-73% -$747K ﹤0.01% 3655
2023
Q3 		$978K Buy
153,279
+261
+0.2% +$2.25K ﹤0.01% 3079
2023
Q2 		$1.7M Sell
153,018
-233,332
-60% -$2.93M ﹤0.01% 2732
2023
Q1 		$5.93M Buy
386,350
+137,189
+55% +$3.02M 0.01% 1791
2022
Q4 		$5.53M Buy
+249,161
New +$3.71M 0.01% 2003

Other funds holding RNAM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

D.E. Shaw & Co's RNAM Position: Q4 2025 in Review

D.E. Shaw & Co sold out of Avidity Biosciences (RNAM) in Q4 2025, closing a stake of 11,577 shares — an estimated $504K sold.

D.E. Shaw & Co first reported a position in RNAM in Q4 2022 and held it in 11 quarters. The position peaked at $50.9M in Q3 2024. 343 funds tracked by Wall St. Rank hold RNAM as of Q4 2025.

  • D.E. Shaw & Co reported no remaining Avidity Biosciences position as of Q4 2025 after selling out during the quarter.
  • D.E. Shaw & Co sold 11,577 Avidity Biosciences shares in Q4 2025, an estimated $504K.
  • D.E. Shaw & Co first reported a position in Avidity Biosciences in Q4 2022 and held it in 11 quarters.
  • D.E. Shaw & Co's Avidity Biosciences position peaked at $50.9M in Q3 2024.
  • 343 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2025.

Based on D.E. Shaw & Co's 13F filing for Q4 2025, filed 17 Feb 2026.